Combinatorial Delivery of Docetaxel- and Erlotinib-Loaded Functionalized Nanostructured Lipid Carriers for the Treatment of Triple-Negative Breast Cancer Using Quality-by-Design Approach.

MLA

Chaudhuri, Aiswarya, et al. “Combinatorial Delivery of Docetaxel- and Erlotinib-Loaded Functionalized Nanostructured Lipid Carriers for the Treatment of Triple-Negative Breast Cancer Using Quality-by-Design Approach.” Pharmaceutics, vol. 16, no. 7, July 2024, p. 926. EBSCOhost, https://doi.org/10.3390/pharmaceutics16070926.

APA

Chaudhuri, A., Kumar, D. N., Srivastava, S. K., Kumar, D., Patil, U. K., Parmar, A. S., Singh, S., & Agrawal, A. K. (2024). Combinatorial Delivery of Docetaxel- and Erlotinib-Loaded Functionalized Nanostructured Lipid Carriers for the Treatment of Triple-Negative Breast Cancer Using Quality-by-Design Approach. Pharmaceutics, 16(7), 926. https://doi.org/10.3390/pharmaceutics16070926

Chicago

Chaudhuri, Aiswarya, Dulla Naveen Kumar, Saurabh Kumar Srivastava, Dinesh Kumar, Umesh Kumar Patil, Avanish Singh Parmar, Sanjay Singh, and Ashish Kumar Agrawal. 2024. “Combinatorial Delivery of Docetaxel- and Erlotinib-Loaded Functionalized Nanostructured Lipid Carriers for the Treatment of Triple-Negative Breast Cancer Using Quality-by-Design Approach.” Pharmaceutics 16 (7): 926. doi:10.3390/pharmaceutics16070926.